LRT Capital Management LLC Has $1.18 Million Position in Novo Nordisk A/S $NVO

LRT Capital Management LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 203.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,222 shares of the company’s stock after buying an additional 14,239 shares during the quarter. LRT Capital Management LLC’s holdings in Novo Nordisk A/S were worth $1,178,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. True Wealth Design LLC raised its holdings in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares in the last quarter. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S during the third quarter valued at approximately $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $30,000. Allianz SE increased its position in shares of Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock worth $32,000 after purchasing an additional 238 shares during the last quarter. Finally, Financial Life Planners acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $33,000. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on NVO shares. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a research report on Tuesday, March 3rd. Finally, HSBC restated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Four equities research analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $49.93.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $38.57 on Tuesday. The company’s 50-day moving average is $49.81 and its 200-day moving average is $51.61. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market capitalization of $172.22 billion, a PE ratio of 11.12 and a beta of 0.74. Novo Nordisk A/S has a fifty-two week low of $35.85 and a fifty-two week high of $82.57.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.